C
Dolby Laboratories, Inc.
DLB
$82.67
-$0.68-0.82%
C
Hold
2/7/2025Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 2/7/2025 due to a large increase in the growth index, volatility index and total return index. EBIT increased 88.83% from $45.06M to $85.1M, total revenue increased 17.12% from $304.81M to $357M, and earnings per share increased from $0.6027 to $0.7.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 2/7/2025 due to a large increase in the growth index, volatility index and total return index. EBIT increased 88.83% from $45.06M to $85.1M, total revenue increased 17.12% from $304.81M to $357M, and earnings per share increased from $0.6027 to $0.7.
C
Hold
11/21/2024Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C from D+ on 11/21/2024 due to a significant increase in the growth index, valuation index and total return index. Operating cash flow increased 446.32% from $21.26M to $116.17M, earnings per share increased from $0.4 to $0.6027, and EBIT increased 25.95% from $40.86M to $51.46M.
Dolby Laboratories, Inc. (DLB) was upgraded to C from D+ on 11/21/2024 due to a significant increase in the growth index, valuation index and total return index. Operating cash flow increased 446.32% from $21.26M to $116.17M, earnings per share increased from $0.4 to $0.6027, and EBIT increased 25.95% from $40.86M to $51.46M.
D
Sell
9/6/2024Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to D+ from C- on 9/6/2024 due to a decline in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was downgraded to D+ from C- on 9/6/2024 due to a decline in the volatility index and total return index.
C
Hold
8/15/2024Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 8/15/2024 due to a substantial decline in the growth index, total return index and volatility index. Operating cash flow declined 88.28% from $181.41M to $21.26M, EBIT declined 61.62% from $106.47M to $40.86M, and earnings per share declined from $1.01 to $0.4.
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 8/15/2024 due to a substantial decline in the growth index, total return index and volatility index. Operating cash flow declined 88.28% from $181.41M to $21.26M, EBIT declined 61.62% from $106.47M to $40.86M, and earnings per share declined from $1.01 to $0.4.
C
Hold
8/4/2023Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 8/4/2023 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 82.86% from $95.7M to $16.4M, earnings per share declined from $0.98 to $0.17, and EBIT declined 69.42% from $109.26M to $33.41M.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 8/4/2023 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 82.86% from $95.7M to $16.4M, earnings per share declined from $0.98 to $0.17, and EBIT declined 69.42% from $109.26M to $33.41M.
C
Hold
8/1/2023Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/1/2023 due to a decline in the growth index, efficiency index and valuation index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/1/2023 due to a decline in the growth index, efficiency index and valuation index.
B
Buy
6/23/2023Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 6/23/2023 due to an increase in the total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 6/23/2023 due to an increase in the total return index.
C
Hold
6/8/2023Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 6/8/2023 due to a decline in the total return index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 6/8/2023 due to a decline in the total return index.
B
Buy
5/8/2023Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C on 5/8/2023 due to a substantial increase in the growth index, valuation index and total return index. Operating cash flow increased 85.37% from $56.4M to $104.54M, earnings per share increased from $0.82 to $0.98, and EBIT increased 16.42% from $93.84M to $109.26M.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C on 5/8/2023 due to a substantial increase in the growth index, valuation index and total return index. Operating cash flow increased 85.37% from $56.4M to $104.54M, earnings per share increased from $0.82 to $0.98, and EBIT increased 16.42% from $93.84M to $109.26M.
C
Hold
2/6/2023Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C from C- on 2/6/2023 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 196.15% from $31.69M to $93.84M, earnings per share increased from $0.2848 to $0.82, and total revenue increased 20.39% from $278.2M to $334.92M.
Dolby Laboratories, Inc. (DLB) was upgraded to C from C- on 2/6/2023 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 196.15% from $31.69M to $93.84M, earnings per share increased from $0.2848 to $0.82, and total revenue increased 20.39% from $278.2M to $334.92M.
C
Hold
12/13/2022Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C- from D+ on 12/13/2022 due to an increase in the volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to C- from D+ on 12/13/2022 due to an increase in the volatility index.
D
Sell
11/21/2022Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to D+ from C- on 11/21/2022 due to a major decline in the growth index, valuation index and total return index. Operating cash flow declined 70.27% from $172.61M to $51.31M, EBIT declined 31.92% from $46.54M to $31.69M, and earnings per share declined from $0.39 to $0.2848.
Dolby Laboratories, Inc. (DLB) was downgraded to D+ from C- on 11/21/2022 due to a major decline in the growth index, valuation index and total return index. Operating cash flow declined 70.27% from $172.61M to $51.31M, EBIT declined 31.92% from $46.54M to $31.69M, and earnings per share declined from $0.39 to $0.2848.
C
Hold
11/16/2022Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 11/16/2022 due to a decline in the total return index, valuation index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 11/16/2022 due to a decline in the total return index, valuation index and dividend index.
C
Hold
11/1/2022Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C from C- on 11/1/2022 due to an increase in the total return index, volatility index and valuation index.
Dolby Laboratories, Inc. (DLB) was upgraded to C from C- on 11/1/2022 due to an increase in the total return index, volatility index and valuation index.
C
Hold
10/7/2022Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 10/7/2022 due to a large decline in the volatility index, growth index and valuation index. Total revenue declined 13.39% from $334.37M to $289.59M, and EBIT declined 4.06% from $48.51M to $46.54M.
Dolby Laboratories, Inc. (DLB) was downgraded to C- from C on 10/7/2022 due to a large decline in the volatility index, growth index and valuation index. Total revenue declined 13.39% from $334.37M to $289.59M, and EBIT declined 4.06% from $48.51M to $46.54M.
C
Hold
3/7/2022Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 3/7/2022 due to a decline in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 3/7/2022 due to a decline in the volatility index and total return index.
C
Hold
2/7/2022Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 2/7/2022 due to a substantial decline in the growth index, valuation index and total return index. Operating cash flow declined 71.16% from $109.77M to $31.66M.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 2/7/2022 due to a substantial decline in the growth index, valuation index and total return index. Operating cash flow declined 71.16% from $109.77M to $31.66M.
B
Buy
11/29/2021Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/29/2021 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 5.53 to 5.32.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/29/2021 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 5.53 to 5.32.
B
Buy
6/16/2021Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 6/16/2021 due to an increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 6/16/2021 due to an increase in the total return index and volatility index.
B
Buy
6/1/2021Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 6/1/2021 due to a major decline in the growth index, valuation index and total return index. EBIT declined 47.84% from $160.9M to $83.93M, earnings per share declined from $1.3 to $0.73, and total revenue declined 18.04% from $389.87M to $319.56M.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 6/1/2021 due to a major decline in the growth index, valuation index and total return index. EBIT declined 47.84% from $160.9M to $83.93M, earnings per share declined from $1.3 to $0.73, and total revenue declined 18.04% from $389.87M to $319.56M.
B
Buy
1/29/2021Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from C+ on 1/29/2021 due to a significant increase in the growth index, valuation index and efficiency index. EBIT increased 435.92% from $30.02M to $160.9M, net income increased 403.92% from $26.83M to $135.2M, and earnings per share increased from $0.2612 to $1.3.
Dolby Laboratories, Inc. (DLB) was upgraded to B from C+ on 1/29/2021 due to a significant increase in the growth index, valuation index and efficiency index. EBIT increased 435.92% from $30.02M to $160.9M, net income increased 403.92% from $26.83M to $135.2M, and earnings per share increased from $0.2612 to $1.3.
C
Hold
1/27/2021Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 1/27/2021 due to an increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 1/27/2021 due to an increase in the total return index and volatility index.
C
Hold
11/18/2020Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 11/18/2020 due to a noticeable decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.66 to $0.2612, net income declined 60.13% from $67.29M to $26.83M, and operating cash flow declined 16.1% from $134.29M to $112.66M.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 11/18/2020 due to a noticeable decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.66 to $0.2612, net income declined 60.13% from $67.29M to $26.83M, and operating cash flow declined 16.1% from $134.29M to $112.66M.
C
Hold
8/5/2020Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/5/2020 due to a substantial decline in the growth index and volatility index. EBIT declined 66.23% from $105.61M to $35.66M, total revenue declined 29.82% from $351.82M to $246.91M, and earnings per share declined from $0.86 to $0.66.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/5/2020 due to a substantial decline in the growth index and volatility index. EBIT declined 66.23% from $105.61M to $35.66M, total revenue declined 29.82% from $351.82M to $246.91M, and earnings per share declined from $0.86 to $0.66.
B
Buy
7/30/2020Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 7/30/2020 due to an increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 7/30/2020 due to an increase in the total return index and volatility index.
C
Hold
7/10/2020Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 7/10/2020 due to a significant increase in the growth index, efficiency index and solvency index. EBIT increased 114.38% from $49.27M to $105.61M, operating cash flow increased 110.98% from $31.16M to $65.74M, and earnings per share increased from $0.47 to $0.86.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 7/10/2020 due to a significant increase in the growth index, efficiency index and solvency index. EBIT increased 114.38% from $49.27M to $105.61M, operating cash flow increased 110.98% from $31.16M to $65.74M, and earnings per share increased from $0.47 to $0.86.
C
Hold
4/21/2020Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 4/21/2020 due to a decline in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 4/21/2020 due to a decline in the total return index and volatility index.
C
Hold
3/18/2020Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 3/18/2020 due to a large decline in the volatility index, total return index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 3/18/2020 due to a large decline in the volatility index, total return index and dividend index.
B
Buy
1/30/2020Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 1/30/2020 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 76.12% from $130.48M to $31.16M, EBIT declined 14.34% from $57.51M to $49.27M, and total revenue declined 2.33% from $298.83M to $291.88M.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 1/30/2020 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 76.12% from $130.48M to $31.16M, EBIT declined 14.34% from $57.51M to $49.27M, and total revenue declined 2.33% from $298.83M to $291.88M.
B
Buy
12/3/2019Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 12/3/2019 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 42.84% from $91.35M to $130.48M, and earnings per share increased from $0.38 to $0.428.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 12/3/2019 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 42.84% from $91.35M to $130.48M, and earnings per share increased from $0.38 to $0.428.
B
Buy
11/19/2019Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 11/19/2019 due to an increase in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 11/19/2019 due to an increase in the volatility index and total return index.
C
Hold
9/26/2019Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 9/26/2019 due to a decline in the valuation index, dividend index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 9/26/2019 due to a decline in the valuation index, dividend index and volatility index.
B
Buy
8/22/2019Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 8/22/2019 due to an increase in the volatility index, valuation index and dividend index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 8/22/2019 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
8/5/2019Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/5/2019 due to a large decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.7 to $0.38, EBIT declined 37.36% from $102.95M to $64.49M, and total revenue declined 10.67% from $338.26M to $302.16M.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 8/5/2019 due to a large decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.7 to $0.38, EBIT declined 37.36% from $102.95M to $64.49M, and total revenue declined 10.67% from $338.26M to $302.16M.
B
Buy
8/2/2019Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/2/2019 due to a large decline in the volatility index, growth index and valuation index. Earnings per share declined from $0.93 to $0.7, and operating cash flow declined 14.15% from $56.95M to $48.89M.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/2/2019 due to a large decline in the volatility index, growth index and valuation index. Earnings per share declined from $0.93 to $0.7, and operating cash flow declined 14.15% from $56.95M to $48.89M.
B
Buy
2/1/2019Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from C on 2/1/2019 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.471 to $0.93, net income increased 96.08% from $50.09M to $98.22M, and EBIT increased 87.35% from $36.66M to $68.69M.
Dolby Laboratories, Inc. (DLB) was upgraded to B from C on 2/1/2019 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.471 to $0.93, net income increased 96.08% from $50.09M to $98.22M, and EBIT increased 87.35% from $36.66M to $68.69M.
C
Hold
12/19/2018Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 12/19/2018 due to a decline in the growth index and total return index. EBIT declined 61.29% from $94.71M to $36.66M, earnings per share declined from $0.78 to $0.471, and operating cash flow declined 21.55% from $142.43M to $111.73M.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 12/19/2018 due to a decline in the growth index and total return index. EBIT declined 61.29% from $94.71M to $36.66M, earnings per share declined from $0.78 to $0.471, and operating cash flow declined 21.55% from $142.43M to $111.73M.
C
Hold
10/15/2018Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 10/15/2018 due to a noticeable increase in the volatility index, total return index and efficiency index. Net income increased 17.72% from $70.63M to $83.15M, and total capital increased 1.58% from $2.15B to $2.19B.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 10/15/2018 due to a noticeable increase in the volatility index, total return index and efficiency index. Net income increased 17.72% from $70.63M to $83.15M, and total capital increased 1.58% from $2.15B to $2.19B.
C
Hold
6/29/2018Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 6/29/2018 due to a decline in the total return index, valuation index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 6/29/2018 due to a decline in the total return index, valuation index and volatility index.
C
Hold
5/7/2018Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 5/7/2018 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 371.7% from $17.15M to $80.89M, earnings per share increased from -$0.8 to $0.66, and EBIT increased 4.99% from $82.04M to $86.14M.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 5/7/2018 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 371.7% from $17.15M to $80.89M, earnings per share increased from -$0.8 to $0.66, and EBIT increased 4.99% from $82.04M to $86.14M.
C
Hold
2/2/2018Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from B on 2/2/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.2078 to -$0.8, net income declined 474.5% from $21.8M to -$81.62M, and operating cash flow declined 78.17% from $78.57M to $17.15M.
Dolby Laboratories, Inc. (DLB) was downgraded to C from B on 2/2/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.2078 to -$0.8, net income declined 474.5% from $21.8M to -$81.62M, and operating cash flow declined 78.17% from $78.57M to $17.15M.
B
Buy
1/29/2018Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 1/29/2018 due to a major increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 1/29/2018 due to a major increase in the total return index and volatility index.
B
Buy
11/17/2017Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/17/2017 due to a substantial decline in the growth index and efficiency index. Earnings per share declined from $0.73 to $0.2078, net income declined 71.34% from $76.04M to $21.8M, and EBIT declined 62.26% from $95.93M to $36.21M.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/17/2017 due to a substantial decline in the growth index and efficiency index. Earnings per share declined from $0.73 to $0.2078, net income declined 71.34% from $76.04M to $21.8M, and EBIT declined 62.26% from $95.93M to $36.21M.
B
Buy
11/15/2017Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 11/15/2017 due to a large increase in the total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 11/15/2017 due to a large increase in the total return index.
B
Buy
8/21/2017Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/21/2017 due to a noticeable decline in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/21/2017 due to a noticeable decline in the total return index and volatility index.
B
Buy
8/4/2017Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 8/4/2017 due to an increase in the growth index, valuation index and efficiency index. Operating cash flow increased 56.57% from $87.59M to $137.14M, EBIT increased 51.59% from $63.28M to $95.93M, and net income increased 50.31% from $50.59M to $76.04M.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 8/4/2017 due to an increase in the growth index, valuation index and efficiency index. Operating cash flow increased 56.57% from $87.59M to $137.14M, EBIT increased 51.59% from $63.28M to $95.93M, and net income increased 50.31% from $50.59M to $76.04M.
B
Buy
8/3/2017Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/3/2017 due to a decline in the total return index, volatility index and valuation index.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 8/3/2017 due to a decline in the total return index, volatility index and valuation index.
B
Buy
7/19/2017Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 7/19/2017 due to an increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 7/19/2017 due to an increase in the total return index and volatility index.
B
Buy
6/14/2017Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 6/14/2017 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 5.22% from $53.37M to $50.59M, EBIT declined 4.21% from $66.07M to $63.28M, and earnings per share declined from $0.51 to $0.49.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 6/14/2017 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 5.22% from $53.37M to $50.59M, EBIT declined 4.21% from $66.07M to $63.28M, and earnings per share declined from $0.51 to $0.49.
B
Buy
3/15/2017Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 3/15/2017 due to an increase in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 3/15/2017 due to an increase in the volatility index and total return index.
B
Buy
2/3/2017Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C on 2/3/2017 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.224 to $0.51, EBIT increased 127.25% from $29.07M to $66.07M, and total revenue increased 14.28% from $233M to $266.27M.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C on 2/3/2017 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.224 to $0.51, EBIT increased 127.25% from $29.07M to $66.07M, and total revenue increased 14.28% from $233M to $266.27M.
C
Hold
1/23/2017Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 1/23/2017 due to a decline in the total return index, volatility index and valuation index.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 1/23/2017 due to a decline in the total return index, volatility index and valuation index.
C
Hold
11/18/2016Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 11/18/2016 due to a large decline in the growth index, valuation index and total return index. EBIT declined 64.19% from $81.19M to $29.07M, earnings per share declined from $0.62 to $0.224, and operating cash flow declined 42.65% from $127.09M to $72.88M.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 11/18/2016 due to a large decline in the growth index, valuation index and total return index. EBIT declined 64.19% from $81.19M to $29.07M, earnings per share declined from $0.62 to $0.224, and operating cash flow declined 42.65% from $127.09M to $72.88M.
B
Buy
11/11/2016Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/11/2016 due to a significant decline in the total return index.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 11/11/2016 due to a significant decline in the total return index.
B
Buy
10/27/2016Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 10/27/2016 due to a large increase in the total return index, valuation index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 10/27/2016 due to a large increase in the total return index, valuation index and volatility index.
B
Buy
9/28/2016Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 9/28/2016 due to a decline in the volatility index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 9/28/2016 due to a decline in the volatility index and dividend index.
B
Buy
6/30/2016Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 6/30/2016 due to a substantial increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 6/30/2016 due to a substantial increase in the total return index and volatility index.
B
Buy
5/6/2016Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 5/6/2016 due to a major increase in the growth index, total return index and valuation index. Earnings per share increased from $0.3 to $0.66, EBIT increased 113.28% from $39.19M to $83.58M, and operating cash flow increased 32.76% from $67.4M to $89.47M.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 5/6/2016 due to a major increase in the growth index, total return index and valuation index. Earnings per share increased from $0.3 to $0.66, EBIT increased 113.28% from $39.19M to $83.58M, and operating cash flow increased 32.76% from $67.4M to $89.47M.
C
Hold
4/25/2016Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 4/25/2016 due to an increase in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 4/25/2016 due to an increase in the total return index and volatility index.
C
Hold
3/11/2016Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index, valuation index and total return index.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index, valuation index and total return index.
C
Hold
2/25/2016Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 2/25/2016 due to an increase in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 2/25/2016 due to an increase in the volatility index and total return index.
C
Hold
2/5/2016Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 2/5/2016 due to a decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.4567 to $0.3, net income declined 33.62% from $46.55M to $30.9M, and operating cash flow declined 19.05% from $83.26M to $67.4M.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 2/5/2016 due to a decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.4567 to $0.3, net income declined 33.62% from $46.55M to $30.9M, and operating cash flow declined 19.05% from $83.26M to $67.4M.
C
Hold
11/27/2015Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 11/27/2015 due to a major increase in the growth index, valuation index and dividend index. Operating cash flow increased 72.82% from $48.18M to $83.26M, earnings per share increased from $0.34 to $0.4567, and total revenue increased 0.45% from $231.7M to $232.75M.
Dolby Laboratories, Inc. (DLB) was upgraded to C+ from C on 11/27/2015 due to a major increase in the growth index, valuation index and dividend index. Operating cash flow increased 72.82% from $48.18M to $83.26M, earnings per share increased from $0.34 to $0.4567, and total revenue increased 0.45% from $231.7M to $232.75M.
C
Hold
7/31/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 7/31/2015 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 72.39% from $174.5M to $48.18M, EBIT declined 42.82% from $78.61M to $44.95M, and earnings per share declined from $0.56 to $0.34.
Dolby Laboratories, Inc. (DLB) was downgraded to C from C+ on 7/31/2015 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 72.39% from $174.5M to $48.18M, EBIT declined 42.82% from $78.61M to $44.95M, and earnings per share declined from $0.56 to $0.34.
C
Hold
7/2/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 7/2/2015 due to a decline in the volatility index, valuation index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 7/2/2015 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
6/17/2015Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 6/17/2015 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 4,965.17% from $3.45M to $174.5M, EBIT increased 45.84% from $53.9M to $78.61M, and earnings per share increased from $0.4 to $0.56.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 6/17/2015 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 4,965.17% from $3.45M to $174.5M, EBIT increased 45.84% from $53.9M to $78.61M, and earnings per share increased from $0.4 to $0.56.
C
Hold
5/7/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 5/7/2015 due to a decline in the volatility index, valuation index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 5/7/2015 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
4/22/2015Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 4/22/2015 due to an increase in the volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 4/22/2015 due to an increase in the volatility index.
C
Hold
4/6/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 4/6/2015 due to a decline in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 4/6/2015 due to a decline in the total return index and volatility index.
B
Buy
3/19/2015Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 3/19/2015 due to an increase in the volatility index, valuation index and dividend index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 3/19/2015 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
3/4/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 3/4/2015 due to a decline in the valuation index, total return index and dividend index.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 3/4/2015 due to a decline in the valuation index, total return index and dividend index.
B
Buy
2/17/2015Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 2/17/2015 due to an increase in the valuation index and volatility index.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 2/17/2015 due to an increase in the valuation index and volatility index.
C
Hold
1/30/2015Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 1/30/2015 due to a significant decline in the growth index and volatility index. Operating cash flow declined 96.15% from $89.58M to $3.45M, earnings per share declined from $0.4384 to $0.4, and EBIT declined 7.2% from $58.08M to $53.9M.
Dolby Laboratories, Inc. (DLB) was downgraded to C+ from B- on 1/30/2015 due to a significant decline in the growth index and volatility index. Operating cash flow declined 96.15% from $89.58M to $3.45M, earnings per share declined from $0.4384 to $0.4, and EBIT declined 7.2% from $58.08M to $53.9M.
B
Buy
12/15/2014Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 12/15/2014 due to a decline in the volatility index and valuation index.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 12/15/2014 due to a decline in the volatility index and valuation index.
B
Buy
11/20/2014Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 11/20/2014 due to a significant increase in the growth index and dividend index. EBIT increased 16.43% from $49.89M to $58.08M, earnings per share increased from $0.38 to $0.4384, and total revenue increased 1.61% from $223.35M to $226.96M.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 11/20/2014 due to a significant increase in the growth index and dividend index. EBIT increased 16.43% from $49.89M to $58.08M, earnings per share increased from $0.38 to $0.4384, and total revenue increased 1.61% from $223.35M to $226.96M.
B
Buy
10/13/2014Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 10/13/2014 due to a major decline in the volatility index, growth index and efficiency index. EBIT declined 52.49% from $105M to $49.89M, earnings per share declined from $0.73 to $0.38, and net income declined 47.57% from $75.87M to $39.78M.
Dolby Laboratories, Inc. (DLB) was downgraded to B- from B on 10/13/2014 due to a major decline in the volatility index, growth index and efficiency index. EBIT declined 52.49% from $105M to $49.89M, earnings per share declined from $0.73 to $0.38, and net income declined 47.57% from $75.87M to $39.78M.
B
Buy
5/20/2014Downgrade
Dolby Laboratories, Inc. (DLB) was downgraded to B from B+ on 5/20/2014 due to a decline in the total return index and volatility index.
Dolby Laboratories, Inc. (DLB) was downgraded to B from B+ on 5/20/2014 due to a decline in the total return index and volatility index.
B
Buy
5/5/2014Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B+ from B on 5/5/2014 due to a major increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.43 to $0.73, EBIT increased 66.29% from $63.15M to $105M, and operating cash flow increased 32.16% from $77.28M to $102.14M.
Dolby Laboratories, Inc. (DLB) was upgraded to B+ from B on 5/5/2014 due to a major increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.43 to $0.73, EBIT increased 66.29% from $63.15M to $105M, and operating cash flow increased 32.16% from $77.28M to $102.14M.
B
Buy
3/10/2014Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 3/10/2014 due to an increase in the volatility index and total return index.
Dolby Laboratories, Inc. (DLB) was upgraded to B from B- on 3/10/2014 due to an increase in the volatility index and total return index.
B
Buy
3/3/2014Upgraded
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 3/3/2014 due to a substantial increase in total return, stability and solvency. The quick ratio increased from 4.05 to 4.95.
Dolby Laboratories, Inc. (DLB) was upgraded to B- from C+ on 3/3/2014 due to a substantial increase in total return, stability and solvency. The quick ratio increased from 4.05 to 4.95.
NYSE
03/10/2025 11:57AM Eastern
Quotes delayed
